Perrigo guides all-in adjusted EPS to $2.25-$2.45 as infant formula moves to discontinued operations
Seeking Alpha · · AI-summarised by FinFlash
Perrigo expects 2026 all-in adjusted EPS of $2.25-$2.45 after shifting its infant formula business into discontinued operations, Seeking Alpha reports from the earnings call. The consumer health group's third-quarter all-in adjusted EPS fell 25% to $0.60, ahead of estimates, on revenue of $989 million from continuing operations. Shares were listed up 0.83%. The reclassification reflects the planned divestiture of the formula unit, which changes the base investors use to measure the company.
So What?
Exiting infant formula narrows Perrigo to over-the-counter health, and the new guidance base complicates comparisons. Watch sale terms and how proceeds are used.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.